EMA UPDATE! DAY ZERO FOR MEDICAL LITERATURE REPORTS

The European Medicines Agency (EMA) has issued a new Q&A for marketing authorization holders (MAHs) to clarify timelines regarding identifying individual case safety reports from physical/hard copy local journals.

The European Medicines Agency (EMA) has issued a new Q&A for marketing authorization holders (MAHs) to clarify timelines regarding identifying individual case safety reports from physical/hard copy local journals.
January 30, 2023

Marketing authorisation holders are requested to review and assess reports of suspected adverse reactions from medical literature to identify and record individual case safety reports (ICSRs).

For ICSRs, described in the medical literature containing the minimum criteria, the clock starts (day zero) on the day when the physical/hard copy local journal is received by the organisation/Marketing authorisation holder/Applicant, and this should be considered equal to performing a literature search in an electronic database.

What do I need to know? When an adverse event is reported in physical media, there could be a lag between the paper’s publication and the MAH finding out about the potential issue. In an update to its pharmacovigilance advice, the EMA has clarified that the clock starts on the day the MAH receives the journal.

For further information, you can contact us at: [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

EVENT | 18th DIA Global QPPV Forum

Amsterdam, 6th and 7th of November Visit Asphalion’s PharmacoVigilance experts at Booth #3! Explore the range of solutions we offer and learn how we can

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting